Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

Abstract Background Multiple myeloma (MM) is an incurable disease. The acquisition of resistance to drugs, including immunomodulatory drugs (IMiDs), has a negative effect on its prognosis. Cereblon (CRBN) is a key mediator of the bioactivities of IMiDs such as lenalidomide. Moreover, genetic alterat...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Mitsuhito Hirano, Yoichi Imai, Yuta Kaito, Takahiko Murayama, Kota Sato, Tadao Ishida, Junichi Yamamoto, Takumi Ito, Muneyoshi Futami, Masaki Ri, Hiroshi Yasui, Tamami Denda, Yukihisa Tanaka, Yasunori Ota, Masanori Nojima, Yasuhiko Kamikubo, Noriko Gotoh, Shinsuke Iida, Hiroshi Handa, Arinobu Tojo
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2021-03-01
Schriftenreihe:	Journal of Experimental & Clinical Cancer Research
Schlagworte:	Multiple myeloma Cereblon Drug-resistance HDAC inhibitor Akt inhibitor Dual HDAC and PI3K inhibitor
Online-Zugang:	https://doi.org/10.1186/s13046-021-01909-7
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!